|Articles|July 5, 2018 (Updated: November 15, 2020)
Why One Korean Biotech Picked New Jersey for U.S. Headquarters
Author(s)Michelle Maskaly
New Jersey is still a top pick for companies when it comes to pharma.
Advertisement
Ki-Young Sohn, chairman and CEO of Enzychem Lifesciences, explains why the company selected New Jersey as the location for their U.S. offices.
He spoke to Pharm Exec during a company event in New York City.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Patent Term Extension: Challenges with Defining and Claiming Approved Biologics
2
Pharmaceutical Executive Daily: FDA Approves Palynziq and Sogroya
3
Real-World Data Brings New Insights to Natural History of Disease Studies
4
FDA Approves New Indication of Palynziq for Patients 12 Years and Older with Phenylketonuria
5